USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC ...

Japanese drugmaker Eisai revealed that its in-house discovered tyrosine kinase inhibitor, Lenvima (lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial ...

US AI-focused start-up Formation Bio and IMIDomics, a precision medicine company focused on immune-mediated inflammatory diseases today announced that Formation Bio has licensed worldwide rights to ...